144 related articles for article (PubMed ID: 38527266)
21. Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma.
Rohaan MW; Borch TH; van den Berg JH; Met Ö; Kessels R; Geukes Foppen MH; Stoltenborg Granhøj J; Nuijen B; Nijenhuis C; Jedema I; van Zon M; Scheij S; Beijnen JH; Hansen M; Voermans C; Noringriis IM; Monberg TJ; Holmstroem RB; Wever LDV; van Dijk M; Grijpink-Ongering LG; Valkenet LHM; Torres Acosta A; Karger M; Borgers JSW; Ten Ham RMT; Retèl VP; van Harten WH; Lalezari F; van Tinteren H; van der Veldt AAM; Hospers GAP; Stevense-den Boer MAM; Suijkerbuijk KPM; Aarts MJB; Piersma D; van den Eertwegh AJM; de Groot JB; Vreugdenhil G; Kapiteijn E; Boers-Sonderen MJ; Fiets WE; van den Berkmortel FWPJ; Ellebaek E; Hölmich LR; van Akkooi ACJ; van Houdt WJ; Wouters MWJM; van Thienen JV; Blank CU; Meerveld-Eggink A; Klobuch S; Wilgenhof S; Schumacher TN; Donia M; Svane IM; Haanen JBAG
N Engl J Med; 2022 Dec; 387(23):2113-2125. PubMed ID: 36477031
[TBL] [Abstract][Full Text] [Related]
22. Complete and long-lasting clinical responses in immune checkpoint inhibitor-resistant, metastasized melanoma treated with adoptive T cell transfer combined with DC vaccination.
Lövgren T; Wolodarski M; Wickström S; Edbäck U; Wallin M; Martell E; Markland K; Blomberg P; Nyström M; Lundqvist A; Jacobsson H; Ullenhag G; Ljungman P; Hansson J; Masucci G; Tell R; Poschke I; Adamson L; Mattsson J; Kiessling R
Oncoimmunology; 2020 Jul; 9(1):1792058. PubMed ID: 32923156
[TBL] [Abstract][Full Text] [Related]
23. Interleukin-2: Old and New Approaches to Enhance Immune-Therapeutic Efficacy.
Dhupkar P; Gordon N
Adv Exp Med Biol; 2017; 995():33-51. PubMed ID: 28321811
[TBL] [Abstract][Full Text] [Related]
24. Efficient harvest of in vivo IL-2-activated CD3+ lymphocytes for adoptive immunotherapy by selective leukapheresis (lymphocytapheresis).
Masucci G; Svensson A; Hansson M; Hansson J; Nakazawa T; Salazar F; Petersson M; Kiessling R
J Hematother; 1997 Jun; 6(3):253-60. PubMed ID: 9234180
[TBL] [Abstract][Full Text] [Related]
25. Prospects for gene therapy and lymphokine therapy for metastatic melanoma.
Sivanandham M; Scoggin SD; Sperry RG; Wallack MK
Ann Plast Surg; 1992 Jan; 28(1):114-8. PubMed ID: 1642399
[TBL] [Abstract][Full Text] [Related]
26. Durable complete responses off all treatment in patients with metastatic malignant melanoma after sequential immunotherapy followed by a finite course of BRAF inhibitor therapy.
Wyluda EJ; Cheng J; Schell TD; Haley JS; Mallon C; Neves RI; Robertson G; Sivik J; Mackley H; Talamo G; Drabick JJ
Cancer Biol Ther; 2015; 16(5):662-70. PubMed ID: 25806780
[TBL] [Abstract][Full Text] [Related]
27. Future perspectives in melanoma research "Melanoma Bridge", Napoli, November 30th-3rd December 2016.
Ascierto PA; Agarwala SS; Ciliberto G; Demaria S; Dummer R; Duong CPM; Ferrone S; Formenti SC; Garbe C; Halaban R; Khleif S; Luke JJ; Mir LM; Overwijk WW; Postow M; Puzanov I; Sondel P; Taube JM; Thor Straten P; Stroncek DF; Wargo JA; Zarour H; Thurin M
J Transl Med; 2017 Nov; 15(1):236. PubMed ID: 29145885
[TBL] [Abstract][Full Text] [Related]
28. Adoptive therapies: quo vadis?
Clark JW; Longo DL
Pathol Immunopathol Res; 1988; 7(6):442-58. PubMed ID: 3070530
[TBL] [Abstract][Full Text] [Related]
29. Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option.
Rohaan MW; van den Berg JH; Kvistborg P; Haanen JBAG
J Immunother Cancer; 2018 Oct; 6(1):102. PubMed ID: 30285902
[TBL] [Abstract][Full Text] [Related]
30. Tumor-infiltrating lymphocytes in melanoma.
Lee S; Margolin K
Curr Oncol Rep; 2012 Oct; 14(5):468-74. PubMed ID: 22878966
[TBL] [Abstract][Full Text] [Related]
31. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients.
Rosenberg SA; Lotze MT; Yang JC; Aebersold PM; Linehan WM; Seipp CA; White DE
Ann Surg; 1989 Oct; 210(4):474-84; discussion 484-5. PubMed ID: 2679456
[TBL] [Abstract][Full Text] [Related]
32. Adoptive cell therapy using tumor-infiltrating lymphocytes for melanoma refractory to immune-checkpoint inhibitors.
Hirai I; Funakoshi T; Kamijuku H; Fukuda K; Mori M; Sakurai M; Koda Y; Kato J; Mori T; Watanabe N; Noji S; Yaguchi T; Iwata T; Ohta S; Fujita T; Tanosaki R; Handa M; Okamoto S; Amagai M; Kawakami Y
Cancer Sci; 2021 Aug; 112(8):3163-3172. PubMed ID: 34101300
[TBL] [Abstract][Full Text] [Related]
33. High dose inhalation interleukin-2 therapy for lung metastases in patients with malignant melanoma.
Enk AH; Nashan D; Rübben A; Knop J
Cancer; 2000 May; 88(9):2042-6. PubMed ID: 10813715
[TBL] [Abstract][Full Text] [Related]
34. [Treatment of metastatic melanoma with interleukin-2].
Chosidow O; Guillaume JC
Ann Dermatol Venereol; 1992; 119(1):65-73. PubMed ID: 1373275
[No Abstract] [Full Text] [Related]
35. Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma.
Yeh S; Karne NK; Kerkar SP; Heller CK; Palmer DC; Johnson LA; Li Z; Bishop RJ; Wong WT; Sherry RM; Yang JC; Dudley ME; Restifo NP; Rosenberg SA; Nussenblatt RB
Ophthalmology; 2009 May; 116(5):981-989.e1. PubMed ID: 19410956
[TBL] [Abstract][Full Text] [Related]
36. Cellular Therapy and Cytokine Treatments for Melanoma.
Borgers JSW; Haanen JBAG
Hematol Oncol Clin North Am; 2021 Feb; 35(1):129-144. PubMed ID: 33759770
[TBL] [Abstract][Full Text] [Related]
37. Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patients.
Besser MJ; Shapira-Frommer R; Treves AJ; Zippel D; Itzhaki O; Schallmach E; Kubi A; Shalmon B; Hardan I; Catane R; Segal E; Markel G; Apter S; Nun AB; Kuchuk I; Shimoni A; Nagler A; Schachter J
J Immunother; 2009 May; 32(4):415-23. PubMed ID: 19342963
[TBL] [Abstract][Full Text] [Related]
38. Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen.
Andersen R; Donia M; Ellebaek E; Borch TH; Kongsted P; Iversen TZ; Hölmich LR; Hendel HW; Met Ö; Andersen MH; Thor Straten P; Svane IM
Clin Cancer Res; 2016 Aug; 22(15):3734-45. PubMed ID: 27006492
[TBL] [Abstract][Full Text] [Related]
39. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2.
Rosenberg SA; Yannelli JR; Yang JC; Topalian SL; Schwartzentruber DJ; Weber JS; Parkinson DR; Seipp CA; Einhorn JH; White DE
J Natl Cancer Inst; 1994 Aug; 86(15):1159-66. PubMed ID: 8028037
[TBL] [Abstract][Full Text] [Related]
40. A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma.
Dudley ME; Wunderlich JR; Yang JC; Hwu P; Schwartzentruber DJ; Topalian SL; Sherry RM; Marincola FM; Leitman SF; Seipp CA; Rogers-Freezer L; Morton KE; Nahvi A; Mavroukakis SA; White DE; Rosenberg SA
J Immunother; 2002; 25(3):243-51. PubMed ID: 12000866
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]